$30,000 of SAVARA INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Monitor prescription drug payment reform. Monitor supply chain. Monitor Medicare/Medicaid issues."
You can find more data on corporate lobbying on Quiver Quantitative.
SVRA Insider Trading Activity
SVRA insiders have traded $SVRA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SVRA stock by insiders over the last 6 months:
- DAVID A RAMSAY sold 20,000 shares for an estimated $121,220
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SVRA Hedge Fund Activity
We have seen 63 institutional investors add shares of SVRA stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP removed 7,000,000 shares (-63.5%) from their portfolio in Q3 2025, for an estimated $24,990,000
- FARALLON CAPITAL MANAGEMENT LLC removed 4,335,000 shares (-63.4%) from their portfolio in Q3 2025, for an estimated $15,475,950
- VR ADVISER, LLC added 3,796,780 shares (+42.7%) to their portfolio in Q3 2025, for an estimated $13,554,504
- ADAR1 CAPITAL MANAGEMENT, LLC removed 1,612,382 shares (-44.8%) from their portfolio in Q3 2025, for an estimated $5,756,203
- MORGAN STANLEY added 1,535,214 shares (+401.2%) to their portfolio in Q3 2025, for an estimated $5,480,713
- ROSALIND ADVISORS, INC. added 1,345,056 shares (+50.7%) to their portfolio in Q3 2025, for an estimated $4,801,849
- BLACKROCK, INC. removed 1,327,333 shares (-13.6%) from their portfolio in Q3 2025, for an estimated $4,738,578
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SVRA Analyst Ratings
Wall Street analysts have issued reports on $SVRA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/23/2025
- Wells Fargo issued a "Overweight" rating on 12/18/2025
- Oppenheimer issued a "Outperform" rating on 11/14/2025
- Citizens issued a "Market Outperform" rating on 11/13/2025
- JMP Securities issued a "Market Outperform" rating on 10/23/2025
- Guggenheim issued a "Buy" rating on 09/09/2025
To track analyst ratings and price targets for SVRA, check out Quiver Quantitative's $SVRA forecast page.
SVRA Price Targets
Multiple analysts have issued price targets for $SVRA recently. We have seen 7 analysts offer price targets for $SVRA in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Andrew S. Fein from HC Wainwright & Co. set a target price of $10.0 on 12/23/2025
- Benjamin Burnett from Wells Fargo set a target price of $9.0 on 12/18/2025
- Andreas Argyrides from Oppenheimer set a target price of $9.0 on 11/14/2025
- Jonathan Wolleben from Citizens set a target price of $10.0 on 11/13/2025
- Jonathan Wolleben from JMP Securities set a target price of $11.0 on 10/23/2025
- Vamil Divan from Guggenheim set a target price of $11.0 on 09/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
